Endo Tools Therapeutics Secures €20 Million Series C to Advance endomina® Platform
Gosselies, Belgium-based Endo Tools Therapeutics (ETT) has announced the closing of €20 million (approximately $23 million) in a Series C financing round to accelerate commercialization of its endomina platform in the United States, Europe, and the Middle East. The oversubscribed round was led by Capricorn Partners via their Capricorn Healthtech Fund II and supported by MGFO, along with existing investors.
The endomina platform consists of a triangulation platform and suturing units that can be affixed to standard endoscopes, creating a flexible therapeutic channel that moves independently. This enables physicians to perform suturing through the mouth via a natural orifice. The system is designed to serve patients with Class I and II obesity seeking a minimally invasive procedure as an alternative to chronic GLP-1 therapy or as part of a combined treatment approach. Endomina remains the only system that can be assembled on the endoscope inside the stomach, offering greater working space and easier instrument access through the esophagus.
The recently FDA-cleared endomina EZFuse system builds on this foundation with a more intuitive design and a single-movement suturing mechanism that streamlines workflow by eliminating unnecessary steps. Early procedural experience has demonstrated significantly faster suturing, allowing physicians to complete procedures more efficiently without changing their established technique. The system is designed to reduce operational burden, minimize user fatigue, and improve procedural consistency, helping hospitals and ambulatory surgery centers optimize resource utilization and expand procedural capacity.
The funding will support U.S., European, and Middle East commercialization and the collection of clinical evidence necessary for a U.S. weight loss marketing indication. The market for advanced endoscopic suturing is large and expanding; in the U.S., millions of patients remain untreated due to the invasiveness of surgery, and global demand for less invasive options is driving double-digit growth in the endoscopic suturing devices market.
Alexandre Chau, CEO of Endo Tools Therapeutics, said the financing marks an important step in scaling the company’s presence in the U.S., European, and Middle East markets. He noted that with the recent FDA clearance of the endomina EZFuse system, the company is introducing a next-generation solution designed to simplify workflow, improve efficiency, and enhance the physician experience. He added that the funding will allow the company to build on that momentum, drive adoption, and continue collecting the data needed to support broader clinical applications.
Filip Pintelon, Investment Partner at Capricorn Partners, said the firm is excited to support ETT at this pivotal stage, adding that the recent FDA clearance of the EZFuse system, combined with strong clinical experience and a clear strategy for U.S. expansion, positions the company to transform gastrointestinal care with minimally invasive endoscopic solutions. By enabling advanced procedures through a natural orifice with a next-generation system designed for speed and efficiency, the endomina platform is positioned to capture a meaningful share of this multibillion-dollar opportunity.
